Friday, 16 October 2026European Markets

SEABIRD EXPLORAT Stock Bullish Momentum With A 15% Jump In The Last 5 Sessions

Loading stream...

(VIANEWS) - Shares of SEABIRD EXPLORAT (Oslo Børs Benchmark Index_GI: SBX.OL) jumped by a staggering 15.51% in 5 sessions from kr3.97 to kr4.58 at 14:39 EST on Monday, after three consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI is jumping 1.03% to kr1,205.88, after five consecutive sessions in a row of gains.

SEABIRD EXPLORAT's last close was kr4.27, 12.86% under its 52-week high of kr4.90.

About SEABIRD EXPLORAT

SeaBird Exploration Plc, together with its subsidiaries, provides marine 2D and 3D seismic data for the oil and gas industry in Europe, Africa, the Middle East, North and South America, and the Asia Pacific. The company offers 2D seismic, and 3D and 3D shallow water acquisition services; and source vessels that provide conventional undershoot, 4D repeat survey, wide azimuth, push reverse, long-term charter and vessel management, in-house source modelling and environmental decay analysis, and spot charter services. It also engages in the marine minerals business. The company was founded in 1996 and is based in Nicosia, Cyprus.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -30.6%.

Yearly Top and Bottom Value

SEABIRD EXPLORAT's stock is valued at kr4.58 at 14:39 EST, under its 52-week high of kr4.90 and way above its 52-week low of kr2.70.

Revenue Growth

Year-on-year quarterly revenue growth grew by 7%, now sitting on 20.16M for the twelve trailing months.

Volume

Today's last reported volume for SEABIRD EXPLORAT is 1365057 which is 216.16% above its average volume of 322660.

Sales Growth

SEABIRD EXPLORAT's sales growth is 112.6% for the ongoing quarter and 223% for the next.

More news about SEABIRD EXPLORAT (SBX.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com